Description
A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide
Contact Name: James Nasman
Please contact NasmanJ@sutterhealth.org about study OCEAN OP-103
Location: REDI (East Bay)
View study details on ClinicalTrials.govPrincipal Investigator
Co-Investigator(s)
Oleg I. Krijanovski, M.D., Ph.D., Uma Suryadevara, MD
Recruitment Status
Completed
Start Date
February 01, 2019
Related Studies
Breast Cancer Chemoprevention in Primary Care at Geisinger
Investigators: Xiaowei (Sherry) Yan, PhD, MS, External PI, Principal Investigator
COVID-19 Impacts on Cancer Care Management, Patient Experience and Care Costs
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH, Cheryl Stults, Ph.D.
Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
Investigator: Su-Ying Liang, Ph.D.
Impact of COVID-19 on Cancer Care Management
Investigators: Su-Ying Liang, Ph.D., Monique de Bruin, M.D., MPH
Implementing Universal Lynch Syndrome Screening Across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizations Contexts
Investigators: Su-Ying Liang, Ph.D., External PI, Principal Investigator, Monique de Bruin, M.D., MPH
Improving Cancer Care
Investigators: Harold (Hal) Luft, Ph.D., Ellis C. Dillon, Ph.D., Su-Ying Liang, Ph.D.
Lung Cancer in Never Smokers: Incidence, Risk Factors and Molecular Characteristics in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Women
Investigators: External PI, Principal Investigator, Harold (Hal) Luft, Ph.D., Su-Ying Liang, Ph.D.
Multilevel Study of Lung Cancer Screening Guidelines Implementation (MUST)
Investigators: Jiang Li, Ph.D., MPH, Dorothy Hung, Ph.D., M.A., MPH
Stupski Serious Illness Program Evaluation
Investigators: Ellis C. Dillon, Ph.D., Sylvia Sudat, PhD